CA3108974C - Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof - Google Patents

Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof Download PDF

Info

Publication number
CA3108974C
CA3108974C CA3108974A CA3108974A CA3108974C CA 3108974 C CA3108974 C CA 3108974C CA 3108974 A CA3108974 A CA 3108974A CA 3108974 A CA3108974 A CA 3108974A CA 3108974 C CA3108974 C CA 3108974C
Authority
CA
Canada
Prior art keywords
compound
formula
acid
occurs
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3108974A
Other languages
English (en)
French (fr)
Other versions
CA3108974A1 (en
Inventor
Benjamin M. Cohen
Gregg B. Feigelson
William W. Leong
John F. Traverse
Chengmin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CA3108974A1 publication Critical patent/CA3108974A1/en
Application granted granted Critical
Publication of CA3108974C publication Critical patent/CA3108974C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3108974A 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof Active CA3108974C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261681477P 2012-08-09 2012-08-09
US61/681,477 2012-08-09
CA2879151A CA2879151C (en) 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2879151A Division CA2879151C (en) 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof

Publications (2)

Publication Number Publication Date
CA3108974A1 CA3108974A1 (en) 2014-02-13
CA3108974C true CA3108974C (en) 2023-04-04

Family

ID=49035933

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3108974A Active CA3108974C (en) 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof
CA2879151A Active CA2879151C (en) 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2879151A Active CA2879151C (en) 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof

Country Status (19)

Country Link
US (2) US9309220B2 (enExample)
EP (2) EP2882736B1 (enExample)
JP (1) JP6444866B2 (enExample)
KR (1) KR20150041650A (enExample)
CN (1) CN104718202B (enExample)
AU (1) AU2013299559B2 (enExample)
BR (1) BR112015002183A2 (enExample)
CA (2) CA3108974C (enExample)
CR (1) CR20150051A (enExample)
EC (1) ECSP15004585A (enExample)
ES (2) ES2712652T3 (enExample)
HK (1) HK1211577A1 (enExample)
IL (1) IL236925A0 (enExample)
IN (1) IN2015DN00845A (enExample)
MX (2) MX385058B (enExample)
PH (1) PH12015500214A1 (enExample)
RU (1) RU2015108057A (enExample)
SG (1) SG11201500984QA (enExample)
WO (1) WO2014025978A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2730763T3 (es) 2010-02-11 2019-11-12 Celgene Corp Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
EP2943201B2 (en) 2013-01-14 2020-07-29 Deuterx, LLC 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
CA2941560A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
CN118638025A (zh) 2017-08-21 2024-09-13 细胞基因公司 制备(s)-4,5-二氨基-5-氧代戊酸叔丁酯的工艺
WO2020072334A1 (en) 2018-10-01 2020-04-09 Celgene Corporation Combination therapy for the treatment of cancer
CN110194760B (zh) * 2019-05-27 2021-08-17 浙江农林大学暨阳学院 制备3-亚苄基-2-(7’-喹啉)-2,3-二氢-异吲哚-1-酮类化合物的方法
CA3159978A1 (en) * 2019-12-02 2021-06-10 Celgene Corporation Therapy for the treatment of cancer
CN113896711A (zh) 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 杂环类免疫调节剂
WO2024064646A1 (en) * 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
CN121002005A (zh) * 2023-04-11 2025-11-21 上海科胜药物研发有限公司 一种芳基甲氧基异吲哚啉衍生物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
JP2008512379A (ja) 2004-09-03 2008-04-24 セルジーン・コーポレーション 置換2−(2,6−ジオキソピペリジン−3−イル)−1−オキソイソインドリン類の調製方法
ME01513B (me) * 2005-06-30 2014-04-20 Celgene Corp Postupak dobijanja spojeva 4-amin0-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona
BRPI0809011A8 (pt) 2007-03-20 2019-01-15 Celgene Corp composto, composição farmacêutica, método de tratamento, controle ou prevenção de uma doença ou distúrbio, e, forma de dosagem unitária única
ES2730763T3 (es) * 2010-02-11 2019-11-12 Celgene Corp Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos
ES2727705T3 (es) 2010-03-08 2019-10-18 Natco Pharma Ltd Forma I de lenalidomida anhidra
ES2671608T3 (es) 2012-02-21 2018-06-07 Celgene Corporation Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona

Also Published As

Publication number Publication date
CN104718202B (zh) 2018-11-20
US20140046058A1 (en) 2014-02-13
JP2015524481A (ja) 2015-08-24
BR112015002183A2 (pt) 2017-07-04
HK1211577A1 (en) 2016-05-27
EP3466942B1 (en) 2022-04-20
MX385058B (es) 2025-03-14
EP2882736B1 (en) 2019-01-09
CN104718202A (zh) 2015-06-17
US9975872B2 (en) 2018-05-22
ECSP15004585A (es) 2015-12-31
IN2015DN00845A (enExample) 2015-06-12
AU2013299559B2 (en) 2017-08-17
US9309220B2 (en) 2016-04-12
CR20150051A (es) 2015-05-11
CA3108974A1 (en) 2014-02-13
RU2015108057A (ru) 2016-09-27
ES2914876T3 (es) 2022-06-17
CA2879151A1 (en) 2014-02-13
MX2015001633A (es) 2015-04-08
KR20150041650A (ko) 2015-04-16
EP2882736A1 (en) 2015-06-17
PH12015500214A1 (en) 2015-04-27
WO2014025978A1 (en) 2014-02-13
ES2712652T3 (es) 2019-05-14
JP6444866B2 (ja) 2018-12-26
CA2879151C (en) 2021-03-30
IL236925A0 (en) 2015-03-31
AU2013299559A1 (en) 2015-02-05
SG11201500984QA (en) 2015-04-29
US20160251333A1 (en) 2016-09-01
EP3466942A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
CA3108974C (en) Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof
CA3142069A1 (en) Aurora kinase inhibitor and use thereof
WO2020210404A1 (en) Dosage forms and regimens for amino acid compounds
KR20200139676A (ko) 아미노산 화합물 및 사용 방법
AU2008282885A1 (en) Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
KR20100116206A (ko) Hsp90 저해제로서의 옥심 유도체
CN104053652A (zh) 用于治疗nk-1受体相关疾病的取代的4-苯基吡啶
PH12015501494B1 (en) Method for producing substituted 5-fluoro-1h-pyrazolopyrimidines
WO2007129111A1 (en) Diazepine derivatives as 5-ht2a antagonists
KR20170132278A (ko) 암 치료에 유용한 1-(사이클로) 알킬 피리딘-2-온의 트리사이클릭 융합 유도체
CN114075219B (zh) 喹啉稠环类衍生物、其制备方法及其在医药上的应用
FI82456B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1-fenyl-1,2,4-tiadiazin-1-oxidderivat.
JP2008150361A6 (ja) ピリジン−メチルスルフィニル化合物の調製方法
JP2008150361A (ja) ピリジン−メチルスルフィニル化合物の調製方法
WO2012107831A1 (en) Method of making a pyridone compound, 5-ethyl-1-phenyl-2-(1h)-pyridone, and intermediates thereof
KR20010090193A (ko) 피리미디논 화합물 및 이의 염의 제조방법
CA3176531A1 (en) 2-heteroarylaminoquinazolinone derivative
EP2963026B1 (en) Substituted (r)-3-(4-methylcarbamoyl-3-fluorophenylamino)tetrahydrofuran-3-enecarboxylic acid (variants) and ester thereof, method for producing and using same
JP2016132660A (ja) 新規イミダゾピリミジンおよびその医薬用途
OA16903A (en) Substituted 4 - phenyl - pyridines for the treatment of NK-1 receptor related diseases.
ITMI20070942A1 (it) Processo per la preparazione di imatinib e suoi intermedi

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210211

EEER Examination request

Effective date: 20210211

EEER Examination request

Effective date: 20210211

EEER Examination request

Effective date: 20210211

EEER Examination request

Effective date: 20210211

EEER Examination request

Effective date: 20210211

EEER Examination request

Effective date: 20210211

EEER Examination request

Effective date: 20210211

EEER Examination request

Effective date: 20210211

EEER Examination request

Effective date: 20210211